A subscription to JoVE is required to view this content. Sign in or start your free trial.
Abstract
Genetics
ERRATUM NOTICE
Important: There has been an erratum issued for this article. Read more …Neural crest cells (NCCs) are migrating multipotent stem cells that can differentiate into different cell types and give rise to multiple tissues and organs. The O9-1 cell line is derived from the endogenous mouse embryonic NCCs and maintains its multipotency. However, under specific culture conditions, O9-1 cells can differentiate into different cell types and be utilized in a wide range of research applications. Recently, with the combination of mouse studies and O9-1 cell studies, we have shown that the Hippo signaling pathway effectors Yap and Taz play important roles in neural crest-derived craniofacial development. Although the culturing process for O9-1 cells is more complicated than that used for other cell lines, the O9-1 cell line is a powerful model for investigating NCCs in vitro. Here, we present a protocol for culturing the O9-1 cell line to maintain its stemness, as well as protocols for differentiating O9-1 cells into different cell types, such as smooth muscle cells and osteoblasts. In addition, protocols are described for performing gene loss-of-function studies in O9-1 cells by using CRISPR-Cas9 deletion and small interfering RNA-mediated knockdown.
Erratum
Erratum: Culturing and Manipulation of O9-1 Neural Crest CellsAn erratum was issued for: Culturing and Manipulation of O9-1 Neural Crest Cells. The Protocol section was updated.
Step 2.1 was updated from:
Prepare basal media for O9-1 cell culture by adding the following in DMEM (final concentrations are indicated): 15% FBS, 0.1 mM minimum essential media (MEM) nonessential amino acids, 1 mM sodium pyruvate, 55 mM beta-mercaptoethanol, 100 U/mL penicillin, 100 U/mL streptomycin, 2 mM L-glutamine, 103 units/mL leukemia inhibitory factor (LIF; added immediately before use, do not add to stock bottle), and 25 ng/mL fibroblast growth factor-basic (bFGF; added immediately before use, do not add to stock bottle).
to:
Prepare basal media for O9-1 cell culture by adding the following in DMEM (final concentrations are indicated): 15% FBS, 0.1 mM minimum essential media (MEM) nonessential amino acids, 1 mM sodium pyruvate, 55 µM beta-mercaptoethanol, 100 U/mL penicillin, 100 µg/mL streptomycin, 2 mM L-glutamine, 103 units/mL leukemia inhibitory factor (LIF; added immediately before use, do not add to stock bottle), and 25 ng/mL fibroblast growth factor-basic (bFGF; added immediately before use, do not add to stock bottle).
Step 5.1.1 was updated from:
To prepare osteogenic differentiation media, dilute the following in alpha-MEM (final concentrations are indicated): 0.1 mM dexamethasone, 100 ng/mL bone morphogenetic protein 2 (BMP2), 50 µg/mL ascorbic acid, 10 mM b-glycerophosphate, 10% FBS, 100 U/mL penicillin, and 100 mg/mL streptomycin.
to:
To prepare osteogenic differentiation media, dilute the following in alpha-MEM (final concentrations are indicated): 0.1 µM dexamethasone, 100 ng/mL bone morphogenetic protein 2 (BMP2), 50 µg/mL ascorbic acid, 10 mM b-glycerophosphate, 10% FBS, 100 U/mL penicillin, and 100 µg/mL streptomycin.
Step 5.2.1 was updated from:
To prepare chondrocyte differentiation media, dilute the following in alpha-MEM (final concentrations are indicated): 5% fetal calf serum (FCS), 1% insulin-transferrin-selenium (ITS), 100 U/mL penicillin, 100 mg/mL streptomycin, 10 ng/mL transforming growth factor beta (TGF-b3), 50 mg/mL ascorbic acid, 10 ng/mL BMP2, 0.1 mM dexamethasone, and 1 mM sodium pyruvate.
to:
To prepare chondrocyte differentiation media, dilute the following in alpha-MEM (final concentrations are indicated): 5% fetal calf serum (FCS), 1% insulin-transferrin-selenium (ITS), 100 U/mL penicillin, 100 µg/mL streptomycin, 10 ng/mL transforming growth factor beta (TGF-b3), 50 µg/mL ascorbic acid, 10 ng/mL BMP2, 0.1 µM dexamethasone, and 1 mM sodium pyruvate.
Step 5.4.1 was updated from:
To prepare glial cell differentiation media, dilute the following in DMEM/F12 (final concentrations are indicated): 1x B-27 supplement, 2 mM L-glutamine, 50 ng/mL BMP2, 100 U/mL penicillin, 100 mg/mL streptomycin, 50 ng/mL LIF, and 1% heat-inactivated FBS.
to:
To prepare glial cell differentiation media, dilute the following in DMEM/F12 (final concentrations are indicated): 1x B-27 supplement, 2 mM L-glutamine, 50 ng/mL BMP2, 100 U/mL penicillin, 100 µg/mL streptomycin, 50 ng/mL LIF, and 1% heat-inactivated FBS.
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved